Spots Global Cancer Trial Database for Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
Official Title: Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.
Study ID: NCT00600249
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Centre Jean Perrin, Clermont-Ferrand, , France
CHU Albert Michallon, Grenoble, , France
Centre Oscar Lambret, Lille, , France
Centre Hospitalier, Montluçon, , France
Institut de Cancérologie de la LOIRE, Saint Priest en Jarez, , France
Hôpital Georges Pianta, Thonon les Bains, , France
Contact Details
Name: Philippe Chollet, MD
Affiliation: Centre Jean Perrin
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
